Peptide Therapeutics Market Analysis | CMI

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
PEPTIDE THERAPEUTICS MARKET ANALYSIS

• Peptide Therapeutics Market, By Type (Branded
  Peptide, Generic Peptide), By Application
  (Cancer, Cardiovascular Disease, Metabolic
  Disease, Respiratory Disease, Infectious Disease,
  Others), By Route of Administration (Oral
  Administration, Parenteral Administration,
  Others), and By Region (North America, Latin
  America, Europe, Asia Pacific, Middle East
  Africa) - Size, Share, Outlook, and Opportunity
  Analysis, 2019 - 2027
• The global peptide therapeutics market is
  estimated to account for US 23,319.3 Mn in terms
  of value and is expected to reach US 57,166.5 Mn
  by the end of 2027.

3
Global Peptide Therapeutics Market Drivers

• Increasing prevalence of metabolic diseases and
  cardiovascular disorders (CVDs) is expected to
  boost growth of the global Peptide Therapeutics
  Market over the forecast period. For instance,
  according to American Heart Associations Heart
  Disease and Stroke Statistics 2018, around 92.1
  million adults in the U.S. are suffering from
  some form of CVD or the after-effects of stroke.
• Moreover, increasing healthcare expenditure is
  also expected to aid in growth of the market. For
  instance, according to the Centers for Medicare
  Medicaid Services (CMS), health spending in the
  U.S. is projected to grow at an average rate of
  5.5 per year for 2018-27 and to reach nearly US
  6.0 trillion by 2027.

4
Statistics

• North America region held dominant position in
  the global peptide therapeutics market in 2018,
  accounting for 42.1 share in terms of value,
  followed by Europe.

5
Global Peptide Therapeutics Market Restraints

• Poor chemical and physical stability and a short
  circulating plasma half-life of naturally
  occurring peptides are expected to hinder growth
  of the global peptide therapeutics market.
• Moreover, presence of stringent safety
  regulations is also restraining the market
  growth. Pharmaceuticals products such as peptide
  therapeutics require better regulatory framework
  as these treat multiple pathological conditions
  by 2020, the regulatory framework is expected to
  be better.

6
Global Peptide Therapeutics Market Opportunities

• RD of new peptides is expected to offer
  lucrative growth opportunities for players in the
  market. For instance, in December 2019, CohBar,
  Inc. announced new preclinical data that
  confirmed the therapeutic potential of a novel
  CohBar peptide in a preclinical model of
  Idiopathic Pulmonary Fibrosis (IPF).
• Moreover, RD in microbiome research is also
  expected to boost growth of the peptide
  therapeutics market. In January 2020, researchers
  from The Chaim Sheba Medical Center, Israel,
  reported that high fructose consumption induced
  metabolic changes and dysbiosis in rats and that
  metabolic changes are probably independent of a
  specific microbiome profile.
• Parenteral sub segment in the route of
  administration segment in global peptide
  therapeutics market was valued at US 16,416.8 Mn
  in 2018 and is expected to reach US 40,790.6 Mn
  by 2027 at a CAGR of 10.5 during the forecast
  period.

7
Market Trends/Key Takeaways

• The market is witnessing increasing adoption of
  new platforms that develop next-generation
  protein or peptide therapeutics. For instance, in
  January 2020, Xenetic Biosciences, Inc. announced
  publication of the data from the completed Phase
  1/2 clinical study of SHP656 ("PSA-recombinant
  Factor VIII", "PSA-rFVIII") in the journal
  Haemophilia. The study used Xenetic's PolyXen
  technology a patent-protected platform
  technology for creating next-generation protein
  or peptide therapeutics.
• The market is also witnessing increasing MA
  activities. For instance, in January 2020,
  Almirall, S.A. acquired Bioniz Therapeutics Inc.,
  a clinical stage biopharmaceutical company that
  develops first-in-class peptide treatments for
  immuno-inflammatory diseases.

8
Regulations

• U.S.
• As per the FDC and PHS act of the U.S. FDA, CDER
  and CBER are responsible for certain part of
  therapeutic proteins
• CDER now has regulatory role, which includes
  premarket review and continuing oversight of
  therapeutic peptides
• 2012 As per FDA, peptides are defined as any
  alpha amino acid polymer with specific defined
  sequence that is 40 amino acids or less in size.
• Since there are various peptide conjugate
  candidates that contain peptides in combination
  with small molecules, the regulatory aspect for
  peptide is still evolving
• The FDA takes into account the history and
  manufacturing aspect of the candidate molecule to
  decide its regulatory pathway Example whether BLA
  would be submitted or NDA needs to be applied
• All the non-clinical studies are carried out as
  per ICH-S6 guidelines

9
(No Transcript)
10
Global Peptide Therapeutics Market Competitive
Landscape

• Major players operating in the global peptide
  therapeutics market include, AstraZeneca plc.,
  Bachem Holding AG, CordenPharma International,
  Eli Lilly and Company, Ipsen S.A, Merck Co.,
  Inc., Novo Nordisk A/S, PolyPeptide Group, and
  Teva Pharmaceutical Industries Ltd.

11
Global Peptide Therapeutics Market Key
Developments

• Major players in the market are focused on
  adopting collaboration strategies to expand their
  product portfolio. For instance, in October 2019,
  PolyPeptide Group collaborated with the Green
  Chemistry and Enabling Technologies Team of IBMM
  (Institut des Biomolécules Max Mousseron), for
  RD greener solutions to produce synthetic
  peptides.
• Major players in the market are also focused on
  adopting MA strategies to expand their product
  portfolio. For instance, in July 2019, Xenetic
  Biosciences, Inc. completed acquisition of the
  novel CAR T (Chimeric Antigen Receptor T Cell)
  platform technology, called XCART, designed to
  use screening technique to identify peptide
  ligands that bind specifically to the unique
  B-cell receptor of malignant tumor cells.

12

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Reference https//www.coherentmarketinsights.com
  /market-insight/peptide-therapeutics-market-1837

13
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

14
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

15

• Thank You!
• Kindly follow CMI Social Media Profiles
  for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/